(Q40964348)

English

Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b.

scientific article published on 19 August 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b. (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

1 reference

based on heuristic

inferred from title

Hiromitsu Kumada

9

object named as

Hiromitsu Kumada

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Masahiro Kobayashi

7

object named as

Masahiro Kobayashi

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

author name string

Phil McEwan

1

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Thomas Ward

2

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Samantha Webster

3

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Yong Yuan

4

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Anupama Kalsekar

5

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Isao Kamae

6

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Ann Tang

8

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

publication date

19 August 2015

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Hepatology Research

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

46

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

423-433

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Global epidemiology of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12570

21 January 2018

Cost-effectiveness of ribavirin plus interferon alpha-2b for either interferon relapsers or non-responders in chronic hepatitis C: a Japanese trial

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12570

21 January 2018

Changing trends in hepatitis C infection over the past 50 years in Japan

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12570

21 January 2018

Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12570

21 January 2018

JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2014 Update for Genotype 1.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12570

21 January 2018

NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12570

21 January 2018

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12570

21 January 2018

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12570

21 January 2018

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12570

21 January 2018

Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12570

21 January 2018

The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12570

21 January 2018

Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12570

21 January 2018

Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12570

21 January 2018

Hepatitis C virus NS5A inhibitors and drug resistance mutations

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12570

21 January 2018

Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12570

21 January 2018

Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12570

21 January 2018

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12570

21 January 2018

The natural history model of hepatitis C virus infection and the economic evaluation of alpha interferon treatment

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12570

21 January 2018

Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12570

21 January 2018

International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12570

21 January 2018

Identifiers

10.1111/HEPR.12570

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40964348&oldid=2122363119"